Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.

Beini LyuYoseob Joseph HwangElizabeth SelvinBrian C JamesonAlex R ChangMorgan E GramsJung-Im Shin

Published in: Journal of general internal medicine (2022)

SGLT2i and GLP1RA confer a lower risk of hypoglycemia compared with sulfonylureas and similar risk compared with DPP4i. Given the known cardiovascular benefits associated with SGLT2i and GL1PRA, our results suggesting the safety of SGLT2i and GL1PRA further support their use.

Keyphrases

type diabetes
rheumatoid arthritis
glycemic control
disease activity
blood pressure
systemic lupus erythematosus
systemic sclerosis